Showing results (1301-1310 of 1,717) with videos related to

Sort By:
Pageof 172
Journal of Hematology & Oncology|August 29, 2021
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trialFarhad Ravandi, Gail J Roboz, Andrew H Wei, et al.
Blood|June 4, 2026
ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid LeukemiaChristopher S Hourigan, Lisanne Beugelink, Jad Othman, et al.
Cancer|June 27, 2025
Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment ConsortiumMichael Boyiadzis, Andrew H Wei, Bruno Paiva, et al.
Blood|March 29, 2020
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trialAndrew H Wei, Pau Montesinos, Vladimir Ivanov, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|August 6, 2018
A perioperative multidisciplinary care bundle reduces surgical site infections in patients undergoing synchronous colorectal and liver resectionLauren S Tufts, Emma D Jarnagin, Jessica R Flynn, et al.
Blood Cancer Journal|October 2, 2021
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Blood|November 30, 2016
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelHartmut Döhner, Elihu Estey, David Grimwade, et al.
International Journal of Colorectal Disease|July 23, 2021
Type of recurrence is associated with disease-free survival after salvage surgery for locally recurrent rectal cancerRosa M Jimenez-Rodriguez, Jonathan B Yuval, Charles-Etienne Gabriel Sauve, et al.
Blood Advances|September 23, 2021
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemiaIng S Tiong, Richard Dillon, Adam Ivey, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|July 6, 2026
[Prognostic impact of WT1 mutations in patients with acute myeloid leukemia]Y Zeng, Y Hui, L Yan, et al.
Pageof 172